Home Clinical Topics FDA approves new treatment for eosinophilic granulomatosis with polyangiitis

FDA approves new treatment for eosinophilic granulomatosis with polyangiitis

Author(s):

On Dec. 12, the U.S. Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication if the first FDA-approved therapy for EGPA.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here